Drug Trial Radar · NCT07628127
A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
332
Planned (sponsor's estimate)
Start
Jul 6, 2026
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Verdiva Bio Dev LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.
Conditions
- Obesity
- Overweight
Interventions
VRB-103Drug
VRB-103 tablets will be administered orally.
PlaceboOther
Placebo tablets will be administered orally.
VRB-101Drug
VRB-101 tablets will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)
- Number of Participants with Adverse Events of Special Interest (AESIs)Time frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)
- Change in Columbia-Suicide Severity Rating Scale (C-SSRS) from BaselineTime frame: Screening up to Day 8 (Arm 1) or End of Treatment (Arm 2: Week 7 and Arm 3: Week 17)
- Change in Patient Health Questionnaire-9 (PHQ-9) Scores from BaselineTime frame: Screening up to End of Study (Arm 1: Day 29, Arm 2: Week 10, and Arm 3: Week 20)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Brisbane, Australia · Recruiting
Nucleus Network
Melbourne, Australia · Recruiting
Veritus
Melbourne, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.